Scope and Boundaries of Regulatory Reliance under NAFDAC-RDRR-005-04

1. Key takeaways

The reliance pathway is the provision most easily overstated by applicants. NAFDAC-RDRR-005-04 draws the boundary in two clauses:

• §3.1.4: reliance is not mutual — when NAFDAC adopts the decision of another authority, it does not follow that the other authority recognizes NAFDAC decisions, and no mutual recognition agreement is created;
• §3.1.5: NAFDAC retains the national decision right, and may still request supplementary information, require verifiable evidence, or reach a different conclusion.

In one sentence: reliance is a door that can be pushed open, but the key is in NAFDAC’s hand, and the door opens in one direction only.

2. Legal basis

3. Expert insights

Insight 1: the nine source categories form an institutional family tree, not a list of countries.

The nine categories under §2.1 are: 2.1.1 WLA/VICH/ICH observer authorities; 2.1.2 ML3 and ML4 regulatory authorities; 2.1.3 the United States EPA; 2.1.4 WHO/WOAH; 2.1.5 the WAHO and ECOWAS regional health mechanisms; 2.1.6 WHO PQ or ISO/IEC 17025 accredited laboratories; 2.1.7 AMRH (the African Medicines Regulatory Harmonization mechanism); 2.1.8 the WHO Collaborative Registration Procedure (CRP, covering medicines, IVDs, vaccines and vector control products); 2.1.9 formal members of the WHO network of National Control Laboratories.

Two points deserve attention. First, the list includes bodies that are not regulators at all (laboratories and international organizations). Second, some entries are regional mechanisms rather than single countries (ECOWAS, AMRH). For that reason the question of whether a given country is recognized is itself imprecise — the correct question is which of the nine categories your evidence comes from.

Insight 2: the non-mutual language of §3.1.4 directly rules out any mutual recognition framing.

In external communications, tender documents and marketing material, reliance must never be described as mutual recognition or bilateral acceptance. Reliance is a one-way act of adoption. This clause sits on the same red line discussed in article 43 on WHO ML3 and ICH membership: international credentials may be used to describe regulatory capability, but they cannot be stretched into device-level mutual recognition. A submission, a tender response or a distributor briefing that slips into recognition language creates a commercial expectation the regulation explicitly denies, and correcting it later costs far more than writing it correctly the first time.

Insight 3: the national decision right in §3.1.5 means supplementary information requests can arrive at any time.

Reliance does not waive the obligation to answer queries. Passing through reliance does not mean exemption from testing — NAFDAC may still raise local applicability questions, such as stability in a tropical climate, data on the local population, or label language. Project schedules therefore cannot be planned on the assumption that reliance equals a fast track; article 49 offers a more realistic pathway estimate.

Insight 4: the procedure under §3.2 is that the applicant informs first, and the authority verifies afterwards.

The structure of §3.2 is: the applicant informs the relevant organisation, and NAFDAC then carries out verification. This places the burden of proof on the applicant — you must lay out the reliance claim, the source category and the evidence chain yourself; NAFDAC will not search for them on your behalf. An applicant who waits for the authority to discover the foreign approvals will simply wait in vain, and the file will move on without them.

Insight 5: reliance and local obligations are additive, not substitutive.

What reliance reduces is the duplicated technical review effort. The local authorized representative, PMS and vigilance, advertisement permits, import permits and change notifications must all still be delivered in full — not one of them may be dropped. As articles 34 and 35 explain, the obligation holders under Regulation 12 expressly include importers and authorized representatives. Budget and staffing for these duties must therefore sit in the Nigerian project plan alongside, never instead of, the reliance argument.

4. Practical recommendations

1. Organize the reliance claim by evidence source category rather than by country list, and cite the corresponding §2.1.x directly in the dossier.
2. Ban the terms mutual recognition and bilateral acceptance from external documents; write only that the reliance mechanism has been adopted.
3. Assemble the evidence package in one pass: approval documents, review reports, laboratory accreditation, GCP/GLP attestations.
4. Schedule on a dual-track basis of reliance plus possible supplementary queries; do not plan production against a pure fast track.
5. Manage the local obligations list separately, so it is never offset against the reliance claim.
6. Track the directive version: -005-04 is the current version, with the review milestone on 10 October 2030.

5. Verification checklist

• □ The reliance claim has been mapped to a specific category under §2.1 (2.1.1–2.1.9).
• □ External documents contain no mutual recognition or bilateral acceptance wording (§3.1.4).
• □ Time and budget have been reserved for supplementary information requests (§3.1.5).
• □ The applicant has proactively informed NAFDAC and provided a complete evidence package under §3.2.
• □ A separate local obligations list has been established and executed item by item.
• □ The citation refers to the current -005-04 version.

Regulatory information verified as of 29 October 2026. All content cited in this document has been checked against the NAFDAC reliance directive (NAFDAC-RDRR-005-04, effective 11 October 2025, review 10 October 2030, §2.1.1–§2.1.9, §2.2, §3.1.4, §3.1.5, §3.2) and the regulation text (S.I. No. 42 of 2024, Regulations 14(2) and 14(3)).

• Local Nigeria resources: GRZAN can coordinate locally licensed import entities and authorized representative resources, covering NAPAMS online submission, dossier screening clearance interfacing, import permits, sample delivery and laboratory analysis support.
• Service capability: classification determination, registration pathway selection, technical documentation (IMDRF ToC) drafting, CMFS and notarization/legalization, GMP and foreign inspection preparation, advertisement permits, vigilance and PMS reporting, change management and renewal.
• Contact: info@grzanglobal.com; website www.grzan.cn.